Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-97540 |
Synonyms | |
Therapy Description |
CC-97540 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, a cell surface tumor antigen, potentially leading to an immune response against CD19-expressing tumor cells and inducing cytotoxicity (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-97540 | CC 97540|CC97540 | CD19 Immune Cell Therapy 65 | CC-97540 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, a cell surface tumor antigen, potentially leading to an immune response against CD19-expressing tumor cells and inducing cytotoxicity (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04231747 | Phase I | CC-97540 | A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Completed | USA | CAN | 0 |